Abstract
4559Background: Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive neoplasm without any approved treatment. The anti-VEGF drugs can produce definite efficacy on renal clear cell carcinoma, but limited for advanced CDC. Gemcitabine plus cisplatin (GC) has showed some activity in patients with advanced CDC. This study was designed to evaluate the efficacy and safety of sorafenib combined with GC as first line treatment in patients with advanced CDC. Methods: This study is a prospective multicenter, single-arm phase II trial. Patients with metastatic, or unresectable CDC by central pathological confirmation and ≥ 1 measurable lesion per RECIST criteria, ECOG PS ≤ 2, and adequate organ function are enrolled. All patients received sorafenib (400mg Bid) combined with GC (cisplatin: 25mg/m2, d1-3; gemcitabine: 1000 mg/m2, d1,d8, for 4 cycles) until disease progression, unacceptable toxicity, or study discontinuation for any other reason. The primary endpoint is PFS. Overall survival, disease ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have